Skip to main content

Mitral Valve Prolapse Echo and Auscultation

Mitral Valve Prolapse: A Comprehensive Review



Mitral Valve Prolapse (MVP) is a common valvular heart condition characterized by the displacement of the mitral valve leaflets into the left atrium during systole. This article provides an in-depth look at the diagnosis, echo findings, and auscultation maneuvers used to identify MVP.


Pathophysiology


In MVP, the mitral valve leaflets bulge backward into the left atrium due to:


1. Myxomatous degeneration: Thickening and redundancy of the valve leaflets.

2. Chordal elongation: Stretching or rupture of the chordae tendineae.


Echo Findings


Echocardiography is the primary diagnostic tool for MVP. Key findings include:


1. Leaflet displacement: > 2 mm displacement of the leaflets beyond the mitral annular plane.

2. Leaflet thickening: Thickening of the leaflets (> 5 mm).

3. Mitral regurgitation: Color Doppler assessment of regurgitant flow.

4. Left atrial enlargement: Enlargement of the left atrium due to chronic regurgitation.


Auscultation Maneuvers


Physical examination plays a crucial role in diagnosing MVP. Auscultation maneuvers include:


1. Mid-systolic click: A high-pitched sound heard best at the apex.

2. Late systolic murmur: A murmur that peaks in late systole, often associated with mitral regurgitation.

3. Valsalva maneuver: Decreases left ventricular volume, increasing the intensity of the murmur.

4. Squatting: Increases left ventricular volume, decreasing the intensity of the murmur.


Clinical Implications


MVP can lead to:


1. Mitral regurgitation: Chronic regurgitation can lead to left ventricular dysfunction.

2. Atrial fibrillation: Increased risk of arrhythmias due to left atrial enlargement.

3. Endocarditis: Increased risk of infective endocarditis.


Management


Treatment strategies for MVP include:


1. Monitoring: Regular echocardiographic follow-up.

2. Medications: Beta blockers or anti-arrhythmics for symptom management.

3. Surgery: Mitral valve repair or replacement in severe cases.


By understanding the technical aspects of MVP, clinicians can provide accurate diagnoses and effective management strategies for patients with this condition.


Visit Echo Library 


Mitral Valve Prolapse (MVP) and Flail Mitral Valve (FMV) are both conditions affecting the mitral valve, but they have distinct differences:


Key Differences


1. Leaflet Motion:

    - MVP: Leaflets bulge backward into the left atrium during systole, but still coapt.

    - FMV: Leaflet or chordae rupture, resulting in severe mitral regurgitation and loss of coaptation.

2. Regurgitation Severity:

    - MVP: Typically mild to moderate mitral regurgitation.

    - FMV: Severe mitral regurgitation due to loss of leaflet coaptation.

3. Echocardiographic Findings:

    - MVP: Leaflet displacement > 2 mm beyond the mitral annular plane.

    - FMV: Visible leaflet or chordae rupture, with severe mitral regurgitation and often a large regurgitant jet.

4. Clinical Presentation:

    - MVP: May be asymptomatic or present with mild symptoms.

    - FMV: Often presents with severe symptoms, such as dyspnea, fatigue, and palpitations, due to acute or severe mitral regurgitation.


Diagnostic Evaluation


1. Echocardiography: Transthoracic echocardiogram (TTE) or transesophageal echocardiogram (TEE) can help diagnose MVP and FMV.

2. Imaging: Careful evaluation of leaflet motion, coaptation, and regurgitant jet severity can help differentiate between MVP and FMV.


Accurate diagnosis and differentiation between MVP and FMV are crucial for guiding management decisions and determining the need for surgical intervention.




#Echocardiography

#Cardiology



Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.